Vicore Pharma Holding AB
VCRE | NASDAQ
$9.73
-$0.07 (-0.71%)
Nov 2, 2026, 10:31 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
Revenue | 3.82M | 109.35M | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 3.58M |
Gross Profit | 3.82M | 109.35M | n/a | n/a | -3.58M |
Operating Income | -454.45M | -190.36M | -321.51M | -290.73M | -32.59M |
Interest Income | 23.89M | 21.08M | 10.54M | 913K | 70.2K |
Pretax Income | -477.47M | -168.89M | -311.33M | -288.81M | -32.8M |
Net Income | -477.47M | -168.63M | -310.94M | -288.42M | -294.97M |
Selling & General & Admin | 67.91M | 50.44M | 44.6M | 37.53M | 2.39M |
Research & Development | 390.35M | 249.26M | 276.29M | 249.97M | 30.05M |
Other Expenses | n/a | n/a | 617K | 3.23M | 154.55K |
Operating Expenses | 458.26M | 299.71M | 321.51M | 290.73M | 32.59M |
Interest Expense | 60K | 8K | 2K | 8K | n/a |
Selling & Marketing Expenses | n/a | n/a | 7.67M | 9.15M | 155.21K |
Cost & Expenses | 458.26M | 299.71M | 321.51M | 290.73M | 32.59M |
Income Tax Expense | n/a | -256K | -384K | -384K | -252.7K |
Shares Outstanding (Basic) | 23.99M | 13.68M | 9.66M | 7.42M | 69.68M |
Shares Outstanding (Diluted) | 23.99M | 13.68M | 9.66M | 7.42M | 69.68M |
EPS (Basic) | -19.90 | -12.30 | -31.80 | -38.82 | -0.47 |
EPS (Diluted) | -19.90 | -12.30 | -31.80 | -38.82 | -0.47 |
EBITDA | -477.41M | -166.64M | -307.9M | -285.19M | -32.07M |
EBIT | -477.41M | -168.88M | -311.32M | -288.8M | -291.93M |
Depreciation & Amortization | n/a | 2.24M | 3.42M | 3.61M | 371.33K |
Add to Watchlist
Select watchlists to add or remove VCRE